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Background: We hypothesized that the factors which may influence health status would dier in patients at dierent
disease stages of chronic obstructive pulmonary disease (COPD). The present study investigated how impairments
in health status were distributed in male patients at each disease stage according to the British Thoracic Society
(BTS) guidelines, and analysed the contribution of the clinical indices, the dyspnoea rating and the psychological
status to the health status of patients at the three disease stages of COPD.
Methods: A total of 218 consecutive male patients with stable COPD were recruited from our outpatient clinic.
All eligible patients completed pulmonary function testing, progressive cycle ergometry, a dyspnoea rating [Medical
Research Council (MRC) dyspnoea scale], an assessment of their anxiety and depression [Hospital Anxiety and
Depression Scale (HADS)], and an assessment of their health status [the St. George’s Respiratory Questionnaire
(SGRQ)]. The patients were categorized into three groups: mild COPD with a FEV1 at 60–79% of the predicted
value, moderate COPD at 40–59% of the predicted value, and severe COPD at below 40% of the predicted value.
Results: Twenty-five patients (11%) had mild COPD, 72 patients (33%) had moderate COPD, and 121 patients
(56%) had severe COPD. Significant dierences were observed for the total score and for three components on the
SGRQ among patients at the three stages (one-way ANOVA, P50?05). The scores for the total SGRQ and for the
activity component were significantly higher for patients with severe COPD than for patients with moderate COPD
[Fisher’s least-significant-dierence (LSD) method, P50?05], and also significantly higher for moderate COPD
patients than for mild COPD patients. The maximal oxygen uptake ( _VO2 max) correlated significantly with the
total SGRQ score in the mild patients [Pearson’s correlation coecient (r)=70?67], but not in the moderate or
severe patients. The MRC dyspnoea scale had strong correlations with the SGRQ in all patient groups
(r=0?53^0?70). Anxiety and depression on the HADS showed moderate correlations with the SGRQ score in the
mild and severe patients (r=0?51^0?57). Multiple regression analysis showed that in patients with mild COPD, the
MRC and _VO2 max accounted for the total score on the SGRQ. Anxiety on the HADS plus the MRC scale
accounted for the total score on the SGRQ in patients with moderate COPD, and anxiety on the HADS, the MRC
scale and the FEV1 significantly influenced the SGRQ severe COPD patients.
Conclusions: The disease staging proposed by the BTS guidelines can separate patients with COPD according to
impairments in their health status. Furthermore, the factors that influence health status diered in patients at the
three disease stages. Our findings support the boundaries used in disease staging and some recommendations from
the BTS guidelines.
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Patients with COPD can be functionally divided into three
stages based on their severity of airflow limitation (1). This
standardized categorization can facilitate prognostication,Received 18 August 1999 and accepted in revised form 26 January
2000.
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0954-6111/00/090841+06 $35?00/0clinical recommendations and health source planning in
patients with COPD (1). The percentage of the predicted
FEV1 is used as the basis for the staging systems proposed
by the British Thoracic Society (BTS) (1), as well as by the
American Thoracic Society (ATS) (2) and the European
Respiratory Society (3). Although the precise boundaries
chosen are rather arbitrary and dier between each set of
guidelines, the following severity ranges were established in
the BTS guidelines: mild COPD with a FEV1 at 60–79%
of the predicted value, moderate COPD at 40–59% of the
predicted value, and severe COPD at below 40% of the
predicted value.# 2000 HARCOURT PUBLISHERS LTD
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or health-related quality of life has been recognized as
one of the more important outcomes in clinical studies
(4,5), and the BTS guidelines emphasized that improving
the quality of life is one of their goals. The relationship
between disease staging and health status warrants further
investigation. For example, Ferrer et al. showed that the
worse disease stage defined by the ATS presented with the
worse health status (6); they also pointed out that patients
at ATS stage I had a poorer health status than reference
groups of healthy people. However, the relationship
between the BTS guidelines and the health status has yet
to be examined.
The major factors that influence the health status
of patients with COPD are dyspnoea and their psycholo-
gical status, whereas physiological parameters such as
their exercise capacity and FEV1 generally do not
contribute very much to impairments in health status (7).
However, it remains unclear whether the same factors
aect patients with an early stage of COPD vs. severe
disease stage. We hypothesized that the factors which may
influence the health status would dier in patients at
the three dierent disease stages. In the present cross-
sectional study, we investigated how impairments in
the health status were distributed in male COPD patients
at each disease stage as defined by the BTS guidelines.
We also evaluated correlations between their health
status and other clinical variables, and analysed the
contribution of pulmonary function, exercise capacity,
the dyspnoea rating and the psychological status to the
health status of COPD patients at the three disease stages.
The health status was assessed with a disease-specific




Patients with stable COPD as defined by the BTS guidelines
(1) were recruited from our outpatient clinic. All of
the patients had at least 6 months of outpatient manage-
ment before entry in order to avoid substantial changes
in subjective parameters induced by any new medical
interventions (9). The entry criteria for this study were:
(i) a maximal FEV1/vital capacity (VC) ratio of less than
0?7 and value of FEV1 of less than 80% of the predicted
for all measurements made over the prior 6 months; (ii) a
smoking history of more than 20 pack-years; (iii) no history
suggestive of asthma; (iv) no exacerbations of their
airflow limitation over the preceding 6 weeks and (v) no
changes in treatment regimen over the preceding 4 weeks.
All eligible patients finished the following examinations on
the same day, including pulmonary function testing,
progressive cycle ergometer testing, an assessment of their
health status and an assessment of their dyspnoea, anxiety
and depression.PULMONARY FUNCTION TESTS
FEV1 and forced vital capacity (FVC) were assessed after
the inhalation of bronchodilators was withheld for at least
12 h. All spirometric flow–volume curves were recorded
according to the method described in the ATS 1994 update
(10). The predicted values for the FEV1 and FVC were
calculated based on the Japan Society of Chest Diseases’
proposal (11). The residual volume (RV) was measured by
the closed-circuit helium method, and the transfer coe-
cient for carbon monoxide (TLCO) was measured using the
single-breath technique (CHESTAC-65V, Chest, Tokyo,
Japan). Patients on long-term domiciliary oxygen therapy
(LTOT) were advised to stop inhaling their oxygen at least
12 h prior to their visits.
SYMPTOM-LIMITED PROGRESSIVE CYCLE
ERGOMETER EXERCISE TEST
A progressive exercise test to a symptom-limited maximum
was performed using an electrically braked cycle ergometer
(Corival WLP-400, Lode, Groningen, The Netherlands) at
60min after the inhalation of bronchodilators, as described
by Ikeda et al. (12). The workload was increased
automatically, and the patients maintained a pedalling
frequency above 40 cycles min71 throughout the test. The
exercise data were recorded with an automated exercise
testing system (Desktop Diagnostics/CPX, Medical
Graphic Corporation, St. Paul, U.S.A.). At the end of
each exercise test, the maximal oxygen uptake ( _VO2) was
calculated. All exercise tests were performed by the same
researcher (M.T.), who did not have any prior knowledge
of the results of the pulmonary function tests.
ASSESSMENT OF THE HEALTH STATUS,
DYSPNOEA, ANXIETY AND DEPRESSION
Health status was assessed by the Japanese version of the
SGRQ (8), which has previously been validated (7). The
SGRQ is divided into three components: symptoms
(distress caused by specific respiratory symptoms), activity
(physical activities that cause or are limited by breath-
lessness) and impacts (social and psychological eects of the
disease). The total score for the SGRQ was also calculated
following the procedures outlined by its developers. The
SGRQ scores range from 0 to 100, with a zero score
indicating no impairment in health status. Dyspnoea was
evaluated with the Japanese version of the MRC dyspnoea
scale, which consists of a five-point grade (13). The
Japanese version of the Hospital Anxiety and Depression
Scale (HADS) (14) was used to evaluate the patients’
anxiety and depression status. The HADS consists of 14
items, seven of which score for anxiety and seven of which
score for depression. It was scored in accordance with the
methods proposed by it original author. The theoretical
scores for anxiety and depression on the HADS range from
0 to 21; a score from 8 to 10 denotes borderline anxiety or
depression and a score over 11 denotes clinical anxiety or
depression. The SGRQ, MRC scale, and HADS were
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(M.T.) checked all of the patients’ answers in order to avoid
possible missing items.
STATISTICAL ANALYSIS
All results are expressed as means+SD. The distribution of
all variables approximated a normal distribution, and thus
parametric tests were used throughout the present study.
Relationships, between two sets of data were analysed using
Pearson’s product-moment correlation test. A P-value of
less than 0?01 was considered to be statistically significant.
Dierences in the physiological values (RV/TLC, TLCO,
and maximal _VO2) and the SGRQ scores among the
subgroups were compared by an analysis of variance
(ANOVA), and statistical significance was established
P50?05. Multiple pairwise comparisons were made with
Fisher’s least-significant-dierence (LSD) method, with the
overall a level set at 0?05. Forward and backward stepwise
multiple regression analysis was performed to identify those
variables which could predict the health status (15).
Variables that were judged to be important for COPD
were used as independent variables for the regression
analysis. The variables were the FEV1 for airflow limita-
tion, the RV/TLC ratio for hyperinflation, the TLCO %
predicted for gas exchange, the _VO2 max for exercise
capacity, the MRC scale for dyspnoea, and anxiety on the
HADS for psychological status. The dependent variable for
this statistical model was the total score from the SGRQ.
All analyses were performed with the statistical program
Statview Version 4?1 (Abacus, Concepts, Berkeley, CA,
U.S.A.).
Results
Patient characteristics are summarized in Table 1. A total
of 218 consecutive male patients with COPD were
evaluated and were categorized into three stages of COPD
based on the BTS guidelines. Twenty-five patients (11%)TABLE 1. Characteristics of 218 consecutive male patients with
Mild COPD
n 25
Age (years) 69 (9)
FEV1(l) 1?89 (0?25)
FEV1(% pred) 70?2 (4?7)
RV/TLC (%) 40?6 (13?1)
TLCO (% pred) 72?4 (15?9)
_VO2 max (mlmin
71) 1019 (323)
The data represent mean (SD).
TLCO: transfer factor for carbon monoxide; max: _VO2 maximal
value; moderate COPD: FEV1 40–59% of the predicted value;
*Significant dierences in the values were observed for patients w
P50?05).
{Significant dierences in the values of those with moderate COhad mild COPD, 72 patients (33%) had moderate COPD,
and 121 patients (56%) had severe COPD. Forty-six
patients were current smokers. Two hundred and eleven
patients (97%) were treated with inhalation of both
b-agonists and anti-cholinergic agents. In addition to the
inhaled agents, oral theophylline (300*800 mg day–1) was
administered in 22 patients (10%), and oral prednisolone
(2?5*10mg day71) in 10 patients (5%). One hundred and
four patients (48%) were also treated with high doses
(1600*2400mg day71) of inhaled beclomethasone dipro-
pionate. Five patients received no medication, and seven
patients were managed with LTOT.
Significant dierences were observed for the RV/TLC
and the _VO2 max (one-way ANOVA, P50?05) The _VO2
max was significantly lower in patients with severe COPD
than in patients with moderate COPD (Fisher’s LSD
method, P50?05; indicated by { in Table 1). The _VO2
max was also significantly lower for moderate COPD
patients than for mild COPD patients (Fisher’s LSD
method, P50?05; indicated by * in Table 1). No significant
dierences in the TLCO were recognized among the three
groups.
Significant dierences were observed for the total score
and for three components on the SGRQ (one-way
ANOVA, P50?05), which are shown in Table 2. The total
score and the activity component on the SGRQ were
significantly higher in patients with severe COPD than in
patients with moderate COPD (Fisher’s LSD method,
P50?05; indicated by { in Table 2), and were also
significantly higher for moderate COPD patients than for
mild COPD patients (Fisher’s LSD method, P50?05;
indicated by * in Table 2). For the symptoms and impacts
components of the SGRQ, the score in the severe COPD
patients was significantly higher than in mild COPD
patients, but was not significantly dierent from that in
moderate COPD patients. No significant dierences in the
HADS scores were recognized among the three groups
based on disease severity.
There were dierent patterns in the relationship between
the SGRQ score and the other clinical variables among theCOPD
Moderate COPD Severe COPD
72 121
69 (7) 68 (6)
1?33 (0?21) 0?75 (0?20)
50?0 (6?1) 28?7 (7?3)
43?2 (10?7) 53?9 (9?8)*{
69?6 (20?8) 63?9 (19?7)
895 (270)* 740 (243)*{
oxygen uptake. Mild COPD: FEV1 60–79% of the predicted
severe COPD: FEV1 below 40% of the predicted value.
ith mild COPD (Fisher’s least-significant-dierence method,
PD (Fisher’s least-significant-dierence method, P50?05).
TABLE 2. The scores for the health status, dyspnoea rating and psychological status in patients at the three disease stages of
COPD
Mild COPD Moderate COPD Severe COPD
n 25 72 121
SGRQ
Symptoms 43?7 (22?1) 48?0 (18?8) 54?7 (19?2)*{
Activity 24?9 (23?9) 34?8 (21?1)* 46?8 (18?4)*{
Impacts 15?5 (15?5) 22?4 (16?3) 26?1 (15?9)*{
Total score 24?2 (17?6) 31?8 (16?2)* 39?0 (15?0)*{
MRC scale 1?5 (0?96) 1?7 (0?8) 2?3 (0?8)*{
HADS
Anxiety 3?6 (2?7) 3?8 (3?2) 4?5 (3?2)
Depression 4?2 (3?1) 4?5 (3?2) 4?7 (3?7)
The data represent means (SD).
SGRQ: the St George’s Respiratory Questionnaire (SGRQ); MRC: Medical Research Council dyspnoea scale; HADS:
Hospital Anxiety and Depression Scale.
*Significant dierences in the scores were observed for patients with mild COPD (Fisher’s least-significant-dierence method,
P50?05).
{Significant dierences in the scores of those with moderate COPD (Fisher’s least-significant-dierence method, P50?05).
TABLE 3. Pearson’s correlation coecients between the SGRQ and other clinical variables in 218 consecutive male patients
with COPD
Total score on the SGRQ
Mild COPD Moderate COPD Severe COPD
n 25 72 121
FEV1 (l) 70?34 [0?098] 70?12 [0?338] 70?24 [0?010]
RV/TLC (%) 70?17 [0?431] 0?40 [0?702] 0?14 [0?137]
TLCO (% pred) 70?32 [0?044] 70?29 [0?028] 70?20 [0?0131]
_VO2 max (mlmin
71) 70?67 [50?001] 70?20 [0?097] 70?39 [50?001]
MRC scale 0?70 [50?001] 0?62 [50?001] 0?53 [50?001]
HADS
Anxiety 0?50 [0?009] 0?31 [0?009] 0?51 [50?001]
Depression 0?53 [0?008] 0?35 [0?003] 0?57 [50?001]
For a definition of the abbreviations, see the footnotes of Tables 1 and 2.
Numbers in the square parentheses represent P-values.
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parameters, FEV1 had low correlation with the SGRQ
score in patients with severe COPD [Pearson’s correlation
coecient (r)=70?24], but there were no significant
correlations in patients with mild or moderate COPD.
The _VO2 max was significantly correlated with the
total SGRQ score in the mild COPD patients (r=70?67),
but not in the moderate or severe patients. The MRC
dyspnoea scale had strong correlations with the SGRQ
score in all patient groups (r=0?53*0?70). Anxiety and
depression on the HADS showed moderate correlations
with the SGRQ score in the mild and severe COPD patients
(r=0?51*0?57).Results of the stepwise multiple regression analyses are
shown in Table 4. In patients with mild COPD, the MRC
scale and _VO2 max accounted for 63% of the variance in
the total score on the SGRQ. Anxiety on the HADS and
the MRC scale accounted for 43% of the total SGRQ score
in patients with moderate COPD. With respect to patients
with severe COPD, Anxiety on the HADS, the MRC scale
and the FEV1 all significantly influenced the SGRQ.
Discussion
The present study showed that the disease staging proposed
by the BTS guidelines could stratify male COPD patients
TABLE 4. Results of the stepwise multiple regression analysis in the cross-sectional study
Total score for the SGRQ
Mild COPD (n=25) Moderate COPD (n=72) Severe COPD
(n=121)
Independent variables
FEV1 (l) — — 0?07 [70?16]
RV/TLC (%) — — —
TLCO (% pred) — — —
_VO2 max (mlmin
71) 0?29 [70?43] — —
MRC scale 0?34 [0?49] 0?32 [0?59] 0?20 [0?41]
Anxiety on HADS — 0?11 [0?21] 0?20 [0?41]
Cumulative R2 0?63 0?43 0?47
All of the values listed above represent a coecient of multiple determination (R2).
Numbers in the square parentheses represent standardized regression coecients.
For a definition of the abbreviations, see the footnotes of Tables 1 and 2.
Missing values indicate that the independent variables were not statistically significant.
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status. We found that the health status of patients with mild
to severe COPD had dierent patterns with respect to its
correlations with physiological parameters, and that the
factors that influenced the impairments in the health status
of COPD patients diered between the three disease stages.
In terms of improving health status, it may be reasonable to
change medical interventions and therapeutic goals in
accordance with the disease stage.
To our knowledge, the present study is the first report on
the relationship between health status and disease staging
proposed by the BTS guidelines. This study demonstrated
that patients in the worst disease stage had the worst scores
on the total SGRQ and on the activity component; the
scores for the symptoms and impacts components also
showed the same tendency. In this regard, the boundaries
chosen for the BTS staging may be appropriate with respect
to the health status. However, the precise boundaries
chosen for the staging are rather arbitrary: the BTS
guidelines selected 80%, 60% and 40% as the cut-o
points for the predicted FEV1 values (1), whereas the ATS
guidelines are set at 80%, 50% and 35% (2). Ferrer et al.
reported that patients in the worst disease stage defined by
the ATS guidelines had the worst health status as evaluated
by the SGRQ and a generic instrument, the Nottingham
Health Profile (6).
In patients with mild COPD, the exercise capacity as
evaluated by the maximal oxygen consumption correlated
significantly with and influenced the total score on the
SGRQ; thus, their mildly decreased exercise capacity
appeared to aect their health status. Our findings support
the recommendations of the BTS guidelines that patients
with mild disease should be encouraged to continue with all
of their usual activities.
Anxiety and dyspnoea played important roles in the
health status of patients with moderate to severe COPD.
Our results are consistent with the previous finding thatanxiety was associated with an impaired health status (16).
The multiple regression analysis showed that anxiety
influenced the health status more in severe COPD patients
than in moderate COPD patients, although there was no
significant dierence in the anxiety score on the HADS
between these two groups. It is conceivable that anxiety and
dyspnoea, both of which correlate with each other, may
impact the health status strongly, especially in patients with
severe COPD. In this regard, psychotherapy for patients
with severe COPD may be considered as one of the
therapeutic options. For example, in their pilot study, Eiser
et al. demonstrated that cognitive and behavioural
psychotherapy produced an improvement in exercise
capacity (17).
The present study confirmed that dyspnoea is one of the
main determinants of health status, and had moderate-
to-strong correlations with impairments in the health status
of patients with mild-to-severe COPD, as previously
reported (7,18). Since even mild breathlessness can impair
the health status of patients with mild COPD, medical
interventions for relieving dyspnoea such as inhaled
bronchodilators may be justified in the early stages of
COPD.
We should mention the limitations of the present study.
Our study included only males, since we experienced
diculty in recruiting a sucient number of female patients
with COPD. Therefore, any generalization of our results to
women with COPD may be unwarranted. Second, since we
recruited only stable patients from our outpatient clinic
who were able to perform a progressive cycle ergometer
test, some of the more symptomatic patients may have been
excluded. We also experienced diculty in enrolling
patients with mild COPD, mainly because they presented
with very few symptoms and thus were reluctant to visit our
clinic in a university setting. Since the cumulative coe-
cients of determination in the regression analysis were not
high, the indices used in this study may not be adequate,
846 T. HAJIRO ET AL.and unknown factors remain which may influence the
health status of patients with COPD.
In conclusion, the disease staging proposed by the BTS
guidelines was able to stratify patients with COPD
according to impairments in their health status. Further-
more, the factors that influenced the health status diered
in patients at the three dierent disease stages. Our findings
support the boundaries of the disease staging and some of
the recommendations proposed by the BTS guidelines.
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